These Mass. biotechs could get drugs approved in 2017 <\/p>\n
David Meeker is the head of Sanofi-Genzyme, which expects to soon win approval for more <\/p>\n
W. Marc Bernsau | Boston Business Journal <\/p>\n
Sanofi-Genzyme, which expects to soon win approval for an eczema drug, has filed a federal lawsuit that seeks to preempt a possible patent challenge by Amgen. <\/p>\n
The Cambridge-based firm, a unit of French pharmaceutical giant Sanofi SA (NYSE: SNY), filed a suit in Boston federal court along with its partner Regeneron Pharmaceuticals (Nasdaq: REGN). The complaint asks a judge to rule that the drug does not infringe a patent held by Amgen (Nasdaq: AMGN). <\/p>\n
David Meeker is the head of Sanofi-Genzyme, which expects to soon win approval for more <\/p>\n
W. Marc Bernsau | Boston Business Journal <\/p>\n
The treatment for atopic dermatitis, which will be sold under the brand name Dupixent, is expected to win FDA approval by March 29. In the complaint, Sanofi-Genzyme and Regeneron described the drug as a game-changer, citing its success in clinical trials. <\/p>\n
<\/p>\n
See more here: These Mass. biotechs could get drugs approved in 2017 David Meeker is the head of Sanofi-Genzyme, which expects to soon win approval for more W. Continue reading
\nSanofi-Genzyme files preemptive legal strike to protect eczema drug - Boston Business Journal<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"